000145422 001__ 145422
000145422 005__ 20200925153819.0
000145422 037__ $$aDZNE-2020-00765
000145422 041__ $$aEnglish
000145422 1001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b0$$eFirst author
000145422 245__ $$aChapter 4 - Therapies for prion diseases
000145422 260__ $$bElsevier$$c2019
000145422 29510 $$aHandbook of Clinical Neurology
000145422 300__ $$a47 - 58
000145422 3367_ $$2ORCID$$aBOOK_CHAPTER
000145422 3367_ $$07$$2EndNote$$aBook Section
000145422 3367_ $$2DRIVER$$abookPart
000145422 3367_ $$2BibTeX$$aINBOOK
000145422 3367_ $$2DataCite$$aOutput Types/Book chapter
000145422 3367_ $$0PUB:(DE-HGF)7$$2PUB:(DE-HGF)$$aContribution to a book$$bcontb$$mcontb$$s1596806700_19233
000145422 4900_ $$v165
000145422 520__ $$aRecent advances in understanding of the molecular biology of prion diseases and improved clinical diagnostic techniques might allow researchers to think about therapeutic trials in Creutzfeldt–Jakob disease (CJD) patients. Some attempts have been made in the past and various compounds have been tested in single case reports and patient series. Controlled trials are rare. However, in the past few years, it has been demonstrated that clinical trials are feasible. The clinicians might face several specific problems when evaluating the efficacy of the drug in CJD, such as rareness of the disease, lack of appropriate preclinical tests and heterogeneous clinical presentation in humans. These problems have to be carefully addressed in future.
000145422 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000145422 7001_ $$0P:(DE-2719)9001208$$aNoor, Aneeqa$$b1
000145422 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b2$$eLast author
000145422 8564_ $$uhttps://reader.elsevier.com/reader/sd/pii/B9780444640123000046?token=BF53112E5F74549C7D447FFE586AF06B4B7E8F2A2811F9F03F7D5879F145D9EF121866DF45FA837E234B047CA240829A
000145422 909CO $$ooai:pub.dzne.de:145422$$pVDB
000145422 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000145422 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001208$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000145422 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000145422 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$aDE-HGF$$bForschungsbereich Gesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000145422 9141_ $$y2019
000145422 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x0
000145422 9201_ $$0I:(DE-2719)6000014$$kGöttingen Pre 2020$$lGöttingen Pre 2020$$x1
000145422 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x2
000145422 980__ $$acontb
000145422 980__ $$aVDB
000145422 980__ $$aI:(DE-2719)5000037
000145422 980__ $$aI:(DE-2719)6000014
000145422 980__ $$aI:(DE-2719)1440011-1
000145422 980__ $$aUNRESTRICTED